Glaxo Wellcome Tritec for H. pylori approved Aug. 8.
GLAXO WELLCOME TRITEC ERA BEGINS: AGENT WILL BE AVAILABLE IN SEPTEMBER following Aug. 8 FDA approval of ranitidine bismuth citrate for use in combination with Abbott's Biaxin (clarithromycin) to treat active duodenal ulcers associated with Helicobacter pylori. Biaxin and Astra Merck's Prilosec (omeprazole) were approved as a combination April 18 and April 15, respectively ("The Pink Sheet" April 22, p. 17).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth